Bausch Health Companies Inc. (NYSE:BHC – Get Rating) was the recipient of some unusual options trading activity on Friday. Stock traders bought 22,560 put options on the company. This represents an increase of 21% compared to the average volume of 18,678 put options.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors and hedge funds have recently modified their holdings of the business. Tobam raised its stake in shares of Bausch Health Companies by 1,685.1% during the third quarter. Tobam now owns 336,774 shares of the company's stock worth $2,340,000 after buying an additional 317,908 shares during the last quarter. Assetmark Inc. grew its holdings in Bausch Health Companies by 454.3% during the second quarter. Assetmark Inc. now owns 10,421 shares of the company's stock valued at $87,000 after purchasing an additional 8,541 shares during the period. WINTON GROUP Ltd acquired a new position in Bausch Health Companies during the second quarter valued at approximately $265,000. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Bausch Health Companies by 3.7% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 778,834 shares of the company's stock valued at $6,510,000 after purchasing an additional 27,923 shares during the period. Finally, Clearline Capital LP acquired a new position in Bausch Health Companies during the second quarter valued at approximately $12,752,000. 66.99% of the stock is owned by institutional investors.

Bausch Health Companies Price Performance

Shares of NYSE BHC traded up $0.38 during trading on Friday, reaching $8.15. The company had a trading volume of 7,917,339 shares, compared to its average volume of 4,648,165. Bausch Health Companies has a 52 week low of $4.00 and a 52 week high of $26.39. The stock has a market cap of $2.95 billion, a PE ratio of 11.10, a PEG ratio of 0.11 and a beta of 0.96. The company has a debt-to-equity ratio of 48.05, a quick ratio of 0.77 and a current ratio of 1.05. The business's 50 day moving average price is $7.14 and its 200-day moving average price is $6.99.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Bausch Health Companies in a research report on Wednesday, October 12th. They issued a "hold" rating on the stock. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $10.60.

Bausch Health Companies Company Profile

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Read More

• Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth
• Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.